Cargando…
Diptoindonesin G, a new Hsp90 drug
Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative diseases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potenti...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841029/ https://www.ncbi.nlm.nih.gov/pubmed/36572186 http://dx.doi.org/10.1016/j.jbc.2022.102826 |
_version_ | 1784869742236925952 |
---|---|
author | Wickramaratne, Anushka Wickner, Sue |
author_facet | Wickramaratne, Anushka Wickner, Sue |
author_sort | Wickramaratne, Anushka |
collection | PubMed |
description | Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative diseases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potential targets for treatments. In the recent JBC Editor’s Pick by Donahue et al., the authors show that diptoindonesin G is a new Hsp90 inhibitor that promotes degradation of the estrogen receptor, an Hsp90 client, without inducing the heat shock response. |
format | Online Article Text |
id | pubmed-9841029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-98410292023-01-19 Diptoindonesin G, a new Hsp90 drug Wickramaratne, Anushka Wickner, Sue J Biol Chem Editors' Pick Highlight Hsp90 is a molecular chaperone that participates in protein folding, activation, and stabilization of substrate proteins. Since many diseases, including cancer, neurodegenerative diseases, and metabolic diseases, are caused by protein misfolding, drugs that inhibit Hsp90 are being pursued as potential targets for treatments. In the recent JBC Editor’s Pick by Donahue et al., the authors show that diptoindonesin G is a new Hsp90 inhibitor that promotes degradation of the estrogen receptor, an Hsp90 client, without inducing the heat shock response. American Society for Biochemistry and Molecular Biology 2022-12-23 /pmc/articles/PMC9841029/ /pubmed/36572186 http://dx.doi.org/10.1016/j.jbc.2022.102826 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Editors' Pick Highlight Wickramaratne, Anushka Wickner, Sue Diptoindonesin G, a new Hsp90 drug |
title | Diptoindonesin G, a new Hsp90 drug |
title_full | Diptoindonesin G, a new Hsp90 drug |
title_fullStr | Diptoindonesin G, a new Hsp90 drug |
title_full_unstemmed | Diptoindonesin G, a new Hsp90 drug |
title_short | Diptoindonesin G, a new Hsp90 drug |
title_sort | diptoindonesin g, a new hsp90 drug |
topic | Editors' Pick Highlight |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9841029/ https://www.ncbi.nlm.nih.gov/pubmed/36572186 http://dx.doi.org/10.1016/j.jbc.2022.102826 |
work_keys_str_mv | AT wickramaratneanushka diptoindonesinganewhsp90drug AT wicknersue diptoindonesinganewhsp90drug |